Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.64 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.64 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.55 |
| ▸ | STAT3 | P40763 | 3/20 | 0.55 |
| ▸ | TNF | P01375 | 1/20 | 0.53 |
| ▸ | IL1B | P01584 | 1/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.53 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.53 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | BCL2 | P10415 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22609417 | 0.88 | CRBN (0.62) | CRBNDDB1DYRK2STAT3TNF | |
| SCHEMBL31710113 | 0.88 | CRBN (0.62) | CRBNDDB1DYRK2STAT3TNF | |
| SCHEMBL26611506 | 0.88 | CRBN (0.61) | CRBNDDB1DYRK2STAT3TNF | |
| SCHEMBL22609707 | 0.88 | CRBN (0.61) | CRBNDDB1DYRK2STAT3TNF | |
| SCHEMBL25565728 | 0.86 | DDB1 (0.69) | CRBNDDB1TNFIL1BTBXA2R | |
| SCHEMBL23884208 | 0.84 | DYRK2 (0.66) | CRBNDDB1DYRK2STAT3HDAC1 | |
| SCHEMBL30864577 | 0.84 | DYRK2 (0.66) | CRBNDDB1DYRK2STAT3HDAC1 | |
| SCHEMBL31091437 | 0.84 | CRBN (0.64) | CRBNDDB1TNFIL1BTBXA2R | |
| SCHEMBL21071039 | 0.84 | CRBN (0.70) | CRBNDDB1STAT3 | |
| SCHEMBL26317544 | 0.84 | CRBN (0.73) | CRBNDDB1STAT3HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | CRBN, CD4, CD74 | CRBN 1/4885DDB1 1404/4885DYRK2 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.